Use of Red Cell Function Testing in Sickle Cell Disease Clinical Trials

Sickle cell disease (SCD) is characterized by hemoglobin S polymerization and diverse red blood cell (RBC) abnormalities that impair microvascular blood flow. The endpoints of the majority of SCD clinical trials include acute pain complications, hemoglobin levels, and markers of hemolysis. Unfortunately, these outcomes do not directly establish whether a therapy normalizes RBC function. We review the role of hemorheological testing in evaluating established, investigational, and potentially curative SCD therapies, and describe the major determinants of abnormal blood flow in SCD, including whole blood viscosity (WBV), RBC deformability, hypoxia-induced sickling, cellular adhesion, and RBC density. Experiences with senicapoc, crizanlizumab, and voxelotor demonstrate how improvement in a single biological or hematologic parameter may fail to establish overall clinical benefit and underscore the need for multimodal functional assessment. Rheological testing may also permit more informative comparisons across hematopoietic stem cell transplantation and gene therapy approaches, for which conventional definitions of a cure remain incomplete. With further analytical standardization and prospective clinical validation, integrated RBC functional profiles could support mechanism-based patient selection, assess treatment response, and identify deterioration before overt acute pain complications or progressive organ injury. Predictive and early detection of clinical deterioration remain investigational. Incorporating rheology into SCD trials may therefore strengthen therapeutic evaluation and support investigation of more individualized clinical care.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-18
DOI
https://doi.org/10.3390/biomedicines14112668
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Use of Red Cell Function Testing in Sickle Cell Disease Clinical Trials

Vivien Sheehan, Mary C. Aliche
1 links
Biomedicines
Hemoglobinopathies and Related Disorders
article

Use of Red Cell Function Testing in Sickle Cell Disease Clinical Trials

Vivien Sheehan, Mary C. Aliche
article en

Abstract

Sickle cell disease (SCD) is characterized by hemoglobin S polymerization and diverse red blood cell (RBC) abnormalities that impair microvascular blood flow. The endpoints of the majority of SCD clinical trials include acute pain complications, hemoglobin levels, and markers of hemolysis. Unfortunately, these outcomes do not directly establish whether a therapy normalizes RBC function. We review the role of hemorheological testing in evaluating established, investigational, and potentially curative SCD therapies, and describe the major determinants of abnormal blood flow in SCD, including whole blood viscosity (WBV), RBC deformability, hypoxia-induced sickling, cellular adhesion, and RBC density. Experiences with senicapoc, crizanlizumab, and voxelotor demonstrate how improvement in a single biological or hematologic parameter may fail to establish overall clinical benefit and underscore the need for multimodal functional assessment. Rheological testing may also permit more informative comparisons across hematopoietic stem cell transplantation and gene therapy approaches, for which conventional definitions of a cure remain incomplete. With further analytical standardization and prospective clinical validation, integrated RBC functional profiles could support mechanism-based patient selection, assess treatment response, and identify deterioration before overt acute pain complications or progressive organ injury. Predictive and early detection of clinical deterioration remain investigational. Incorporating rheology into SCD trials may therefore strengthen therapeutic evaluation and support investigation of more individualized clinical care.

BiomedicinesVol. 14(11)
Emory University (US), Children's Healthcare of Atlanta (US)
Good health and well-being
Hemoglobinopathies and Related Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon